Heterogeneity in proteomic risk factors for coronary heart disease by sex and menopause status

Am J Prev Cardiol. 2026 Jun 29;31:101727. doi: 10.1016/j.ajpc.2026.101727. eCollection 2027 Jan.ABSTRACTBACKGROUND: Coronary heart disease (CHD) is the leading cause of morbidity and mortality worldwide, yet current prediction tools do not fully capture sex differences in risk. Menopause further mod

J Janina M Herold

Inverse Association of the Life's Crucial 9 Score With MAFLD: An Exploratory Mediation Analysis of the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index

Int J Endocrinol. 2026 Oct 17;2026:1340865. doi: 10.1155/ije/1340865. eCollection 2026.ABSTRACTBACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is strongly associated with cardiovascular disease. Life's Crucial 9 (LC9), an expanded cardiovascular health metric incorporating p

H Hanlu Li

Elevated lipoprotein (a) and large apo(a) isoforms in Omani patients: a distinct cardiovascular risk profile

No abstractAm J Prev Cardiol. 2026 Aug 3;31:101781. doi: 10.1016/j.ajpc.2026.101781. eCollection 2027 Jan.NO ABSTRACTPMID:42893023 | PMC:PMC13676121 | DOI:10.1016/j.ajpc.2026.101781

A Amani Al Khaifi

Use of an AI metabolomics score to predict cardiovascular risk among patients with Psoriasis in the MGB and UK Biobanks

Am J Prev Cardiol. 2026 Jun 6;31:101696. doi: 10.1016/j.ajpc.2026.101696. eCollection 2027 Jan.ABSTRACTBACKGROUND: Systemic inflammation in psoriasis accelerates atherosclerosis and confers excess cardiovascular risk that is not fully captured by traditional clinical predictors. Metabolomic profilin

C Christos P Kotanidis

Proteomic and metabolomic correlates of sociodemographic factors and their associations with kidney and cardiovascular outcomes: findings from the Chronic Renal Insufficiency Cohort

No abstractAm J Prev Cardiol. 2026 Jul 4;31:101737. doi: 10.1016/j.ajpc.2026.101737. eCollection 2027 Jan.NO ABSTRACTPMID:42893009 | PMC:PMC13676058 | DOI:10.1016/j.ajpc.2026.101737

I Insa M Schmidt

Ticagrelor versus prasugrel following PCI in acute coronary syndromes and high-risk coronary artery disease: A meta-analysis of one-year randomized trial outcomes

Am Heart J Plus. 2026 Oct 5;71:100930. doi: 10.1016/j.ahjo.2026.100930. eCollection 2026 Nov.ABSTRACTBACKGROUND: Guidelines recommend potent P2Y12 inhibitors over clopidogrel following percutaneous coronary intervention. Whether ticagrelor- or prasugrel-based dual antiplatelet therapy (DAPT) provide

M Mohamed Ibrahim Gbreel

Insights Into RP2-Associated Retinopathy: From Molecular Basis to Clinical Translation

Hum Mutat. 2026 Oct 17;2026:1839164. doi: 10.1155/humu/1839164. eCollection 2026.ABSTRACTPathogenic variants in RP2 cause X-linked RP2-associated retinopathy, a rare inherited retinal disorder typically characterized by childhood onset and progression to severe visual impairment within the first thr

N Nina Bögershausen

Coronary artery disease polygenic risk score and recurrent cardiovascular events after coronary artery revascularization: A UK Biobank analysis

No abstractAm J Prev Cardiol. 2026 Jul 25;31:101770. doi: 10.1016/j.ajpc.2026.101770. eCollection 2027 Jan.NO ABSTRACTPMID:42892973 | PMC:PMC13676052 | DOI:10.1016/j.ajpc.2026.101770

A Aman Goyal

Lipoprotein(a), smoking, and diabetes are additive but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome

No abstractAm J Prev Cardiol. 2026 Aug 31;31:101747. doi: 10.1016/j.ajpc.2026.101747. eCollection 2027 Jan.NO ABSTRACTPMID:42892971 | PMC:PMC13676043 | DOI:10.1016/j.ajpc.2026.101747

G Gregory G Schwartz

Cardiometabolic Risk Factors, Obesity Phenotypes, and Novel Anthropometric Indices in Patients With Acute Coronary Syndrome: A Hospital-Based Case-Control Study in Central India

Cureus. 2026 Sep 17;18(9):e116416. doi: 10.7759/cureus.116416. eCollection 2026 Sep.ABSTRACTBACKGROUND: Acute coronary syndrome (ACS) is the most severe manifestation of cardiovascular disease and disproportionately affects South Asians at a younger age than Western populations. Body mass index (BMI

S Sanskruti Boob

HeatRisk and air quality risk recommendations: A narrative review and action algorithm for the care of people at risk for and living with cardiovascular disease

Am J Prev Cardiol. 2026 Jun 15;31:101704. doi: 10.1016/j.ajpc.2026.101704. eCollection 2027 Jan.ABSTRACTBACKGROUND: Cardiovascular disease remains the leading cause of mortality worldwide and is influenced by climate change-related exposures. Non-optimal temperature and poor air quality exposure wor

E Elizabeth Beveridge

Impact of High-sensitivity C-reactive protein testing on statin use in primary prevention: A national multicenter analysis

No abstractAm J Prev Cardiol. 2026 Jul 14;31:101745. doi: 10.1016/j.ajpc.2026.101745. eCollection 2027 Jan.NO ABSTRACTPMID:42892955 | PMC:PMC13676055 | DOI:10.1016/j.ajpc.2026.101745

D Danh Q Nguyen

Comparison of AI-enabled cardiac chambers volumetry based on non-gated chest CT scans with echocardiography: An AI-CVD study within the Multi-Ethnic Study of Atherosclerosis (MESA)

No abstractAm J Prev Cardiol. 2026 Jul 9;31:101731. doi: 10.1016/j.ajpc.2026.101731. eCollection 2027 Jan.NO ABSTRACTPMID:42892953 | PMC:PMC13676041 | DOI:10.1016/j.ajpc.2026.101731

S Seyed Reza Mirjalili

Association of dual-pathway antithrombotic therapy with primary patency after iliofemoral venous stenting: a multicenter cohort study

Res Pract Thromb Haemost. 2026 Sep 15;10(7):106965. doi: 10.1016/j.rpth.2026.106965. eCollection 2026 Oct.ABSTRACTBACKGROUND: The optimal antithrombotic strategy after iliofemoral venous stenting remains uncertain.OBJECTIVES: This study aimed to evaluate the association of dual-pathway antithromboti

C Can Chen

Mouse models to study von Willebrand factor in thrombosis: a scoping review

Res Pract Thromb Haemost. 2026 Jul 15;10(7):106863. doi: 10.1016/j.rpth.2026.106863. eCollection 2026 Oct.ABSTRACTBACKGROUND: von Willebrand factor (VWF) plays a significant role in blood coagulation and inflammation and is a key driver of many thrombotic conditions. Identifying appropriate mouse mo

V Veronica DeYoung

MYLK c.4079G>A, p.(Gly1360Asp) Variant Associated With Hereditary Thoracic Aortic Diseases and Early Onset Aortic Dissection

Ann Hum Genet. 2026 Oct 18. doi: 10.1111/ahg.70064. Online ahead of print.ABSTRACTAIMS: Thoracic aortic aneurysms and dissections are major causes of sudden cardiovascular death. We aimed to evaluate the clinical significance of the MYLK c.4079G>A, p.(Gly1360Asp) variant in Finnish families with her

M Minja Virtanen

Subclavian steal syndrome: a case report

Harefuah. 2026 Oct;166(9):614-616.ABSTRACTAn 80-year-old female presented to the emergency department with dizziness, generalized weakness, and exertional dyspnea. Physical examination revealed a significant inter-arm systolic blood pressure discrepancy. Computed tomography angiography (CTA) of the

H Haim Fanshel

Metabolic health is a stronger determinant than obesity for cardiovascular disease incidence: a meta-analysis of longitudinal cohort studies

Int J Obes (Lond). 2026 Oct 17. doi: 10.1038/s41366-026-02237-6. Online ahead of print.ABSTRACTOverweight and obesity are established risk factors for cardiovascular diseases (CVDs), yet heterogeneity in metabolic health among individuals with varied body mass index (BMI) complicates risk assessment

Z Zeinab Ghorbani

Zyxin protects against hypertensive nephropathy by restraining FAK/Skp2-CDK8/YAP signaling in tubular epithelial cells

Inflamm Res. 2026 Oct 17;75(1):245. doi: 10.1007/s00011-026-02373-9.ABSTRACTBACKGROUND: Tubulointerstitial fibrosis and inflammation are hallmark pathological features of hypertensive nephropathy (HN), yet the underlying molecular mechanisms remain elusive. Zyxin, a focal adhesion protein, has been

W Wei Huang

Immune checkpoint inhibitor-associated myocarditis: clinical and mechanistic insights

Inflamm Res. 2026 Oct 17;75(1):247. doi: 10.1007/s00011-026-02397-1.ABSTRACTBACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can cause immune-related adverse events, including potentially severe cardiovascular toxicities. Although rare, immune checkpoint inhib

H Heng Liu

Persistent hypertension and left ventricular remodeling after stenting for coarctation of the aorta: a single-center cohort study

J Hum Hypertens. 2026 Oct 17. doi: 10.1038/s41371-026-01237-3. Online ahead of print.ABSTRACTPersistent hypertension (HTN) remains common after covered stent implantation for coarctation of the aorta (CoA). However, existing evidence is derived predominantly from surgical repair cohorts and cross-se

K Kexin Zhao

Single-cell RNA sequencing identifies a proinflammatory S100a8/a9+ macrophage subset contributing to acute kidney injury

CONCLUSIONS: S100a8/a9 plays a regulatory role in CD11b^(+)Ly6c^(high) macrophage population differentiation, contributing to endotoxemia-induced AKI. S100a8/a9 blockade may be a novel therapeutic strategy for the prevention or attenuation of AKI.Inflamm Res. 2026 Oct 17;75(1):242. doi: 10.1007/s000

T Ting Ren

Pharmacokinetic evidence of an abiraterone-rosuvastatin drug interaction resulting in rhabdomyolysis and acute kidney injury

J Clin Lipidol. 2026 Oct 4:S1933-2874(26)00541-6. doi: 10.1016/j.jacl.2026.09.025. Online ahead of print.ABSTRACTStatins are among the most common causes of medication-associated rhabdomyolysis. Abiraterone, an oral androgen biosynthesis inhibitor, has been reported to increase the risk of statin-as

E Erik Dove

Echocardiographic estimates of pulmonary artery acceleration time and mortality risk in older adults

Am J Med. 2026 Oct 18:S0002-9343(26)00537-1. doi: 10.1016/j.amjmed.2026.06.049. Online ahead of print.ABSTRACTBACKGROUND: Pulmonary artery acceleration time (PAAT) is an echocardiographic measure associated with pulmonary artery pressure. Although reduced PAAT has been linked to pulmonary hypertensi

J Joel Anthony Nations